Citations

Clear

949 citation(s) found for "Li, Bryan".

Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
Haugen, Bryan R. , Sherman, Eric J. , Dadu, Ramona , Gianoukakis, Andrew G. , Wolfe, Eric, Foster, Nathan R. , Wirth, Lori J. , French, Jena D. , Worden, Francis P. , Konda, Bhavana , Bowles, Daniel W.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 6512-6512

10.1200/jco.2020.38.15_suppl.6512 Get It

6512 Background: Lenvatinib is an approved therapy for patients with RAIR DTC. While the overall response rate (ORR) is high, few patients achieve a complete response (CR) and most patients eventually have progressive disease (PD). Combination lenvatinib and pembrolizumab is being explored in many different cancers, and this combination has been approved for advanced endometrial carcinoma. Methods: Patients with RAIR DTC with Response Evaluation Criteria in Solid Tumor (RECIST v1.1) measurable PD (<14 months (mo) prior to registration) were enrolled in this single-arm multicenter phase II study. Patients were excluded if they had received previous VEGFR-directed multikinase therapy. The lenvatinib starting dose was 20 mg/day orally and pembrolizumab was 200mg IV every 3 weeks. The primary endpoint was CR. ORR, progression-free survival (PFS) and safety graded by Common Terminology Criteria for Adverse Events v4.0 were secondary endpoints. Results: Thirty patients were enrolled. The median age was 62.5 years, and 53% of the patients were women. Seventy percent of patients had grade 3 adverse events (AEs) and 10 percent had grade 4 AEs. There were no treatment-related deaths. The most common > grade 3 AEs were hypertension (47%), weight loss (13%), maculopapular rash (13%), leukopenia (7%), diarrhea (7%) and oral mucositis (7%). Twenty-one patients (70%) required lenvatinib dose reduction. Of 29 evaluable patients, 18 (62%) had a partial response (PR) and 10 (35%) had stable disease (SD). The clinical benefit rate (ORR +SD) was 97%. Median time to tumor nadir was 7.4 mo (1.6-17.8 mo). Median PFS was not yet reached. The PFS at 12 months was 74%. Median time on therapy was 9.9 mo (3.2-18.9 mo). Fourteen patients are continuing therapy (7.6-18.9 mo). Six of these patients (43%) have not yet reached tumor size nadir. Three patients (10%) had > 80% target tumor shrinkage. Conclusions: Lenvatinib plus pembrolizumab is reasonably tolerated in patients with RAIR DTC. To date, there have been no documented complete responses. Combination lenvatinib plus pembrolizumab therapy has a high ORR in patients with RAIR DTC. Continuation of this study will help determine the depth and length of the responses. Clinical trial information: NCT02973997 .
Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).
Weinstein, Gregory S., Mehra, Ranee , García, Joaquín J. , Chung, Christine H. , Gillison, Maura L. , Duvvuri, Umamaheswar , O’Malley, Bert W. , Özer, Enver , Thomas, Giovana R. , Koch, Wayne M. , Kupferman, Michael E. , Méndez, Eduardo, Ferris, Robert L. , Flamand, Yael , Li, Shuli , Quon, Harry , Bell, R. Bryan , Saba, Nabil F. , Lango, Miriam N. , Burtness, Barbara

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 6500-6500

10.1200/jco.2020.38.15_suppl.6500 Get It

6500 Background: ECOG-ACRIN 3311 examines reduced postoperative therapy in patients with “intermediate risk” p16+ oropharynx cancer (OPC) undergoing primary transoral surgical management. We report the primary endpoint of 2-year progression free survival (PFS) for patients randomized to 50Gy vs 60Gy without chemotherapy. Methods: Between December 2013 and July 2017, 82 credentialed surgeons performed transoral resection (TOS) for 519 OPC patients (cT1-2 stage III/IV AJCC7 without matted neck nodes); post-operative management was determined by pathologically assessed risk. Among 353 eligible and treated patients, Arm A enrolled 10% (N=37) for clear margins, 0-1 nodes, no extranodal extension (ENE)), Arms B (50Gy, N=102) or C (60Gy, N=104) randomized 58%, for clear/close margins, 2-4 + nodes, or ENE ≤1mm, while Arm D (N=110, 60-66Gy plus weekly cisplatin, 40 mg/m2, positive margin with any T stage, >4 + nodes, or >1mm ENE) enrolled 31%. Arm D assignment was based on >1mm ENE (76%), > 4 nodes (27%), and/or positive margins (11%). Intermediate-risk patients were stratified by smoking history (>10 pk-yr). Of the 80 pts (15%) deemed ineligible, 28 had scans/labs not done per protocol, however treatment arm distribution for all patients mirrored that for the 353 pts eligible and treated. Results: Median follow-up was 31.8 months. 2 yr PFS for Arms A, B and C were 93.9% (90% CI=87.3%, 100%), 95.0% (90% CI=91.4%, 98.6%) and 95.9% (90% CI=92.6%, 99.3%) respectively, while Arm D was 90.5% (90% CI=85.9%, 95.3%). The regimen of TOS + low-dose radiation is considered worthy of further study, since the primary endpoint of the upper bound of the 90% CI (in the intermediate risk group) exceeding 85% was met. Of 17 progression events, 7 were locoregional. There were 10 distant recurrences: Arm A=1, Arm B=2, Arm C=4, Arm D=3. Grade III/IV treatment-related AE rates were 15%/2% during surgery, 13%/2% for Arm B and 25%/0% for Arm C. There were 2 treatment-related deaths (one surgical and one Arm D). Conclusions: Transoral resection of p16+ OPC is safe and results in good oncologic outcome, presenting a promising deintensification approach. For patients with low-risk disease, 2-yr PFS is favorable without post-operative therapy. For those with uninvolved surgical margins, <5 involved nodes, and minimal (<1mm) ENE, reduced dose postoperative RT without chemotherapy appears sufficient. Transoral surgery plus 50Gy should be compared to optimal non-surgical therapy in a phase III trial. Clinical trial information: NCT01898494 .
Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers.
Overman, Michael J. , Fogelman, David R. , Wolff, Robert A. , Morris, Van K. , Kee, Bryan K. , Dasari, Arvind , Raghav, Kanwal , Shureiqi, Imad , Johnson, Benny , Parseghian, Christine Megerdichian , Eng, Cathy , Garg, Naveen , Kopetz, Scott

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 4047-4047

10.1200/jco.2020.38.15_suppl.4047 Get It

4047 Background: BRAFV600E mutations occur in fewer than 10% of all patients (pts) with metastatic colorectal cancer (mCRC) and arise from sessile serrated adenomas. Despite efficacy with targeted therapies against MAPK signaling and with immunotherapies in this population, survival outcomes for pts with BRAFV600E mCRC in general are poor. Characteristics distinguishing pts with BRAFV600E mCRC with favorable versus unfavorable outcomes have not been well annotated. Methods: Records of 188 pts with BRAFV600E mCRC evaluated at MD Anderson Cancer Center between 3/2010-1/2020 were reviewed. Pts with the shortest and longest metastatic survival (N = 25 for each group) were compared. Associations between prognostic group and clinical/pathologic features were measured by odds ratio and for median survival by log-rank testing. Results: Median metastatic survival differed between the 2 BRAFV600E mCRC populations (8.6 vs 84 months, p < .0001). Pts with poor survival more commonly had primary tumors arising from the hepatic flexure/proximal transverse colon (44% vs 16%, p = .04) and more frequent hepatic involvement (75% vs 28%, p = .001). Pts with favorable survival were more likely to develop metachronous metastases (52% vs 16%, p = .01), have fewer distant organ involvement (median 1 vs 2, p = .02), and undergo definitive locoregional therapy to metastatic disease (44% vs 0%, p = .01). Microsatellite instability (36% vs 4%, p = .008) and a history of tobacco use (44% vs 16%, p = .04) were associated with a favorable prognosis. Durable responses to MAPK-targeted therapies (5/25) and immunotherapy (3/25) were noted in the favorable group. Conclusions: Pts with BRAFV600E mCRC can achieve excellent long-term survival which belies conventional context and is driven by locoregional and systemic treatment options alike. Anatomic localization of the primary tumor and prior exposures may highlight environmental influences on tumor biology which account for the clinical heterogeneity of pts with BRAFV600E mCRC.
Altered Metabolism of Mothers of Young Children with Autism Spectrum Disorder: A Case Control Study
Hollowood-Jones, Kathryn , Coleman, Devon M. , Ramamoorthy, Sivapriya , Melnyk, Stephan, James, S. Jill , Woodruff, Bryan K. , Pollard, Elena L., Snozek, Christine L.H. , Chuah, Joshua , Adams, James B. , Krüger, Uwe , Hahn, Juergen

Mayo Clinic

No container title available | May 20, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-29600/v1 Get It

Abstract Background: Previous research studies have demonstrated abnormalities in the metabolism of mothers of young children with autism. Method: Metabolic analysis was performed on blood samples from 30 mothers of young children with Autism Spectrum Disorder (ASD-M) and from 29 mothers of young typically-developing children (TD-M). Targeted metabolic analysis focusing on the folate one-carbon metabolism (FOCM) and the transsulfuration pathway (TS) as well as broad metabolic analysis were performed. Statistical analysis of the data involved both univariate and multivariate statistical methods. Results: Univariate analysis revealed significant differences in 5 metabolites from the folate one-carbon metabolism and the transsulfuration pathway and differences in an additional 48 metabolites identified by broad metabolic analysis, including lower levels of many carnitine-conjugated molecules. Multivariate analysis with leave one-out cross validation allowed classification of samples as belonging to one of the two groups with 93% sensitivity and 97% specificity with five metabolites. Furthermore, each of these five metabolites correlated with 8-15 other metabolites indicating that there are five clusters of correlated metabolites. In fact, all but 5 of the 50 metabolites with the highest area under the receiver operating characteristic curve were associated with the five identified groups. Many of the abnormalities appear linked to low levels of folate, vitamin B12, and carnitine-conjugated molecules. Conclusions: Mothers of children with ASD have many significantly different metabolite levels compared to mothers of typically developing children at 2-5 years after birth.
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease
Grau, Laura , McNair, Bryan , Harris, Peter C. , Brosnahan, Godela , Torres, Vicente E. , Steinman, Theodore I., Yu, Alan S.L. , Chapman, Arlene B., Chonchol, Michel , Nowak, Kristen L. , Nowak, Kristen L , Harris, Peter C , Torres, Vicente E , Yu, Alan S L , Gitomer, Berenice Y , Wolf, Myles Selig

Mayo Clinic

Kidney360 | May 12, 2020 | Volume: 1 | Issue: 7 | Pages: 648-656

10.34067/kid.0001692020 | PMID 33305291 Get It

Background Higher serum intact fibroblast growth factor 23 (iFGF23) was associated with disease progression in participants with autosomal dominant polycystic kidney disease (ADPKD) in the HALT-PKD Studies. PKD mutation is also an important determinant of progression. We hypothesized that serum levels of iFGF23 and vitamin D metabolites (1,25-dihydroxyvitamin D [1,25(OH) 2 D] and 25-hydroxyvitamin D [25[OH]D]) differ according to ADPKD mutation and differentially predict clinical end points according to genotype (significant interaction between genotype and mineral metabolites). Methods A total of 864 individuals with ADPKD who participated in the HALT-PKD Study A or B and had measurements of mineral metabolites (1,25[OH] 2 D, 25[OH]D, iFGF23) were categorized by PKD mutation (PKD1 truncating, PKD1 nontruncating, PKD2, or no mutation detected [NMD]). The association of the interactions of genotype × iFGF23, genotype × 1,25(OH)2D, and genotype × 25(OH)D with ( 1 ) annualized change in eGFR; ( 2 ) mean annualized percentage change in height-corrected total kidney volume (Study A only); and ( 3 ) time to a composite of 50% reduction in eGFR, ESKD, or death were evaluated using linear regression and Cox proportional hazards regression. Results Median (interquartile range) iFGF23 differed (PKD1 truncating, 55.8 [40.7–76.8]; PKD1 nontruncating, 49.9 [37.7–71.0]; PKD2, 49.0 [33.8–70.5]; NMD, 50.3 [39.7–67.4] pg/ml; P =0.03) and mean±SD 1,25(OH) 2 D differed (PKD1 truncating, 32.8±12.8; PKD1 nontruncating, 33.4±12.5; PKD2, 34.1±13.1; NMD, 38.0±14.6 pg/ml; P =0.02) according to PKD genotype. There was a significant interaction between iFGF23 and genotype ( P =0.02) for the composite end point in fully adjusted models, but no significant interaction between 1,25(OH) 2 D or 25(OH)D and genotype for clinical end points. Conclusions ADPKD genotype interacts significantly with FGF23 to influence clinical end points. Whereas the worst outcomes were in individuals with a PKD1-truncating or -nontruncating mutation and the highest iFGF23 tertile, risk of the composite end point differed according to iFGF23 the most in the PKD1-nontruncating and PKD2 groups.
BRCA1Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis
Kalachand, Roshni , Stordal, Britta , Madden, Stephen F. , Chandler, Benjamin C. , Cunningham, Julie M. , Goode, Ellen L. , Ruscito, Ilary , Braicu, Elena Ioana , Ignatov, Atanas , Katsaros, Dionyssios , Lu, Karen H. , Carey, Mark , Timms, Kirsten M. , Podgórska, Agnieszka , Swisher, Elizabeth M. , Bernards, Sarah S., Ó’Riain, Ciarán, O’Toole, Sharon , O’Leary, John , Bowtell, David D.L. , Thomas, David M. , Prieske, Katharina , Joosse, Simon A. , Woelber, Linn, Chaudhry, Parvesh, Runnebaum, Ingo B. , Hennessy, Bryan T. , Cunningham, Julie, Swisher, Elizabeth M , Bowtell, David D , Joosse, Simon A , Sehouli, Jalid , Yu, Kai , Mills, Gordon B. , Kupryjańczyk, Jolanta , Rzepecka, Iwona K. , McAlpine, Jessica N. , Woelber, Linn Lena , Häfner, Norman

Mayo Clinic

JNCI: Journal of the National Cancer Institute | May 11, 2020 | Volume: 112 | Issue: 12 | Pages: 1190-1203

10.1093/jnci/djaa070 | PMID 32413141 Get It

AbstractBackgroundBRCA1 methylation has been associated with homologous recombination deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated tubal and ovarian cancer (OC) do not consistently support improved survival following platinum chemotherapy. We examine the characteristics of BRCA1-methylated OC in a meta-analysis of individual participant data.MethodsData of 2636 participants across 15 studies were analyzed. BRCA1-methylated tumors were defined according to their original study. Associations between BRCA1 methylation and clinicopathological characteristics were evaluated. The effects of methylation on overall survival (OS) and progression-free survival (PFS) were examined using mixed-effects models. All statistical tests were 2-sided.Results430 (16.3%) tumors were BRCA1-methylated. BRCA1 methylation was associated with younger age and advanced-stage, high-grade serous OC. There were no survival differences between BRCA1-methylated and non–BRCA1-methylated OC (median PFS = 20.0 vs 18.5 months, hazard ratio [HR] = 1.01, 95% CI = 0.87 to 1.16; P = .98; median OS = 46.6 vs 48.0 months, HR = 1.02, 95% CI = 0.87 to 1.18; P = .96). Where BRCA1/2 mutations were evaluated (n = 1248), BRCA1 methylation displayed no survival advantage over BRCA1/2-intact (BRCA1/2 wild-type non–BRCA1-methylated) OC. Studies used different methods to define BRCA1 methylation. Where BRCA1 methylation was determined using methylation-specific polymerase chain reaction and gel electrophoresis (n = 834), it was associated with improved survival (PFS: HR = 0.80, 95% CI = 0.66 to 0.97; P = .02; OS: HR = 0.80, 95% CI = 0.63 to 1.00; P = .05) on mixed-effects modeling.ConclusionBRCA1-methylated OC displays similar clinicopathological features to BRCA1-mutated OC but is not associated with survival. Heterogeneity within BRCA1 methylation assays influences associations. Refining these assays may better identify cases with silenced BRCA1 function and improved patient outcomes.
Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Henry, Nathaniel J , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alamene, Genet Melak, Alanezi, Fahad , Alebel, Animut , Alema, Niguse Meles , Ali, Beriwan Abdulqadir, Alikhani, Mahtab , Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Amini, Saeed, Amit, Arianna Maever L. , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Asghari, Babak , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azari, Samad , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Bagli, Eleni , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banach, Maciej , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barrero, Lope H. , Barzegar, Akbar , Baye, Bayisa Abdissa , Bekuma, Tariku Tesfaye , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Borzì, Antonio Maria , Bražinová, Alexandra, Брико, Н. И. , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chanie, Wagaye Fentahun, Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaudhary, Neha , Cho, Daniel , Chowdhury, Mohiuddin Ahsanul Kabir , Chu, Dinh‐Toi , Colquhoun, Samantha , Costa, Vera Marisa , Damiani, Giovanni , Dávila-Cervantes, Claudio Alberto , Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Derakhshani, Afshin , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Eftekhari, Aziz , Ehsani‐Chimeh, Elham , Elemineh, Demelash Abewa , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fatahi, Yousef , Fekadu, Wubalem , Ferede, Tomas Y, Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Feyissa, Garumma Tolu , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebre, Abadi Kahsu , Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Gedefaw, Getnet , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Ghashghaee, Ahmad , Gholamian, Asadollah , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Gubari, Mohammed Ibrahim Mohialdeen , Guo, Yuming , Haagsma, Juanita A. , Hafezi‐Nejad, Nima , Hall, Brian J. , Hamadeh, Randah R , Hasan, Md. Mehedi , Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Ilić, Irena , Ilić, Milena , Inbaraj, Leeberk Raja , Indriasih, Endang , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Islam, M. Mofizul , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahani, Mohammad Ali, Jahanmehr, Nader , Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kadel, Rajendra , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kebede, Hafte Kahsay , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Kelkay, Bayew, Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Ejaz Ahmad , Khan, Maseer , Khanna, Tripti, Shadmani, Fatemeh Khosravi , Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kumar, G Anil , Kumar, Manasi , Kumaresh, Girikumar, Kurmi, Om , Kuti, Oluwatosin, Lami, Faris , Lamichhane, Prabhat , Lang, Justin J. , Lasrado, Savita , Leasher, Janet L , Lee, Shaun Wen Huey , Lenjebo, Tsegaye Lolaso , Li, Shanshan , Linn, Shai , Liu, Xuefeng , Lunevičius, Raimundas , Lyons, Ronan A , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Malagón-Rojas, Jeadran , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mansouri, Borhan , March, Lyn , Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Meles, Gebrekiros Gebremichael , Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mirzaei-Alavijeh, Mehdi , Mithra, Prasanna , Moazen, Babak , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammad, Karzan Abdulmuhsin , Mezerji, Naser Mohammad Gholi, Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Shafiu , Mohammed, Jemal , Mohebi, Farnam , Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Masoud , Moradi, Ghobad , Moradpour, Farhad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Murthy, Srinivas , Musa, Kamarul Imran , Mustafa, Ghulam , Nabhan, Ashraf , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Nyasulu, Peter S. , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Okunga, Emmanuel , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Asante, Kwaku Oppong , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Pham, Hai Quang , Pinheiro, Marina , Полибин, Р. В. , Polinder, Suzanne, Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Ranganathan, Kavitha , Rao, Sowmya J, Rashedi, Vahid , Rastogi, Prateek , Rathi, Priya , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Renzaho, André M. N. , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Ríos-González, Carlos Miguel , Sabde, Yogesh , Saddik, Basema , Safari, Saeed , Safarpour, Hamid , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salehi, Farkhonde , Zahabi, Saleh Salehi , Salem, Marwa Rashad , Salem, Hosni , Salman, Omar , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Sawyer, Susan M. , Saxena, Sonia , Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sharifi, Hamid , Sheikh, Aziz , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Smarandache, Catalin-Gabriel , Soleymani, Bija, Soriano, Joan B. , Soyiri, Ireneous N , Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Suleria, Hafiz Ansar Rasul , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tamiru, Animut Tagele , Tarigan, Ingan Ukur , Tefera, Yibekal Manaye , Tekle, Merhawi Gebremedhin , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Bedaso, Asres , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Car, Lorainne Tudor , Ullah, Saif , Ullah, Irfan , Umar, Maida, Unnikrishnan, Bhaskaran , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Teklay, Girmay , Werdecker, Andrea , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Yusefzadeh, Hasan, Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zamanian, Maryam , Zhang, Zhi-Jiang , Zhang, Yunquan , Zodpey, Sanjay , Dandona, Lalit , Dandona, Rakhi , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Sartorius, Benn , Vos, Theo , Topór‐Mądry, Roman , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Stein, Dan J , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Belete, T , Liu, Zichen, Roberts, Nicholas L S , Abdoli, Amir , Abdollahpour, Ibrahim , Ahmed, Rushdiá , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Al‐Hajj, Samar , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Saeed, Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Bayati, Mohsen , Bedi, Neeraj , Behzadifar, Masoud , Benjet, Corina L. , Benseñor, Isabela M. , Bibi, Sadia , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Constantin, María Magdalena , Daryani, Ahmad , Demeke, Feleke Mekonnen , Demis, Asmamaw , Forooshani, Zahra Sadat Dibaji, Duko, Bereket , Zaki, Maysaa El Sayed , Adane, Daniel, Eskandarieh, Sharareh , Yeheyis, Tomas Y. , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gill, Tiffany K. , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Haghparast‐Bidgoli, Hassan , Hamidi, Samer , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hayat, Khezar , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Rade, Bayew Kelkay , Khalil, Ibrahim A, Khammarnia, Mohammad , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Vecchia, Carlo La , Lansingh, Van Charles , Laryea, Dennis Odai , Latifi, Arman , Lauriola, Paolo , Levi, Miriam , Lopez, Alan D , Lotufo, Paulo A. , Majeed, Azeem , Malekzadeh, Reza , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Melese, Addisu Dagnaw , Aschalew, Zeleke , Mengesha, Meresa Berwo , Meštrović, Tomislav , Mirică, Andreea , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Patton, George , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rawaf, Salman , Ribeiro, Ana Isabel , Ronfani, Luca , Roshandel, Gholamreza , Saad, Anas M. , Sabour, Siamak , Safari‐Faramani, Roya , Salamati, Payman, Sarker, Abdur Razzaque , Sayyah, Mehdi , Sepanlou, Sadaf Ghajarieh , Shahabi, Saeed , Siabani, Soraya , Singh, Jasvinder A. , Smith, Emma U.R. , Soheili, Amin , Soltanian, Ali Reza , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tadesse, Degena Bahrey , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Bach Xuan , Tran, Khanh Bao , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondafrash, Dawit Zewdu , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , Wu, Aimin , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zarei, Ahmad , Zare, Fatemeh, Degenhardt, Louisa J , Dharmaratne, Samath Dhamminda , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | April 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i96-i114

10.1136/injuryprev-2019-043494 | PMID 32332142 Get It

Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.
DYRK3 Encodes an Inhibitor of Erythroid Differentiation and Is Expressed at High Levels in Patients with Anemia.
Porcher, Julie C., Chadderton, Antony, Laubscher, Kevin, Jaworski, D., Bell, William N., Hoffman, Bryan E., Erickson‐Miller, Connie L., Steensma, David P. , Lager, Joanne J.

Mayo Clinic

Blood | April 18, 2020 | Volume: 110 | Issue: 11 | Pages: 3661-3661

10.1182/blood.v110.11.3661.3661 Get It

Abstract Background: Many patients (pts) with anemia due to impaired erythropoiesis fail to respond to currently available erythropoiesis-stimulating agents or do not wish to receive these agents due to safety concerns. For these pts, novel approaches are needed. DYRK3, an evolutionarily conserved member of an emerging family of serine-threonine kinases, is expressed at high levels in erythropoietic progenitors; murine models suggest that DYRK3 selectively inhibits red cell production during stress erythropoiesis. We sought to determine DYRK3 expression in pts with anemia, and whether in vitro inhibition of DYRK3 augments erythropoiesis. Methods: We performed quantitative RT-PCR for DYRK3 and 4 control genes using whole peripheral blood (WPB) from 14 healthy persons, 5 pts with anemia due to multiple myeloma (MM), and 3 pts with anemia of chronic disease (ACD); in addition, peripheral blood mononuclear cells (PBMCs) were assayed in the 3 ACD and 5 MM pts and bone marrow mononuclear cells (BMMCs) in the MM pts. Erythrocyte subpopulations (CD36+, CD71+, and dual CD36+/CD71+) were quantified by flow cytometry. CFU-E growth was measured from PBMCs and BMMCs in the presence of varying concentrations of GSK626616, an orally bioavailable first-generation DYRK3 kinase inhibitor. Results: Normalized expression of DYRK3 in WPB was 7.2 fold higher in MM pts (p=0.0001) and 3.4 fold higher in pts with ACD (p=0.026) compared to healthy controls. DYRK3 expression was proportional to the degree of anemia, and WPB and PBMC expression of DYRK3 in MM pts correlated well with BMMC expression. The level of DYRK3 expression was proportional to the population of marrow CD36+/CD71+ erythroid progenitors, and inversely proportional to the size of the more mature CD36−/CD71+ population, suggesting that high DYRK3 expression is associated with maturation arrest in humans at a stage of erythroid differentiation roughly corresponding to pre-Ter119pos/CD71high inhibition observed in murine models. Although incubation of pt-derived BMMC or PBMC with GSK626616 at concentrations up to 30 μM, either in the presence or absence of physiological concentrations of erythropoietin, did not augment in vitro CFU-E formation, CFU-E growth overall was poor in the pt samples studied. Conclusion: DYRK3 is expressed at high levels in pts with anemia due to neoplasia or inflammation, and elevated DYRK3 expression is associated with decreased numbers of CD36−/CD71+ red cells. Further studies of the effects of DYRK3 antagonists on human erythropoiesis in vitro are necessary, and clinical trials in anemic patients will be required to determine if DYRK3 antagonists can reverse DYRK3-associated inhibition.
Advances in the diagnosis of fungal pneumonias
Kelly, Bryan T. , Pennington, Kelly M. , Kelly, Bryan T., Limper, Andrew H.

Mayo Clinic

Expert Review of Respiratory Medicine | April 15, 2020 | Volume: 14 | Issue: 7 | Pages: 703-714

10.1080/17476348.2020.1753506 | PMID 32290725 Get It

Wolff–Parkinson–White syndrome: De novo variants and evidence for mutational burden in genes associated with atrial fibrillation
Coban‐Akdemir, Zeynep , Charng, Wu‐Lin , Azamian, Mahshid S. , Paine, Ingrid S. , Punetha, Jaya , Valdés, Santiago O. , Cannon, Bryan C. , Zapata, Gladys, Hernandez, Patricia, Jhangiani, Shalini N. , Doddapaneni, HarshaVardhan , Hu, Jianhong , Boricha, Fatima, Muzny, Donna M. , Boerwinkle, Eric , Yang, Yaping , Gibbs, Richard A. , Wehrens, Xander H.T. , Cannon, Bryan, Gibbs, Richard A , Posey, Jennifer E , Lalani, Seema R , Wehrens, Xander H T , Grochowski, Christopher M. , Gambin, Tomasz , Belmont, John W. , Kim, Jeffrey J. , Miyake, Christina Y. , Lupski, James R.

Mayo Clinic

American Journal of Medical Genetics Part A | March 31, 2020 | Volume: 182 | Issue: 6 | Pages: 1387-1399

10.1002/ajmg.a.61571 | PMID 32233023 Get It

AbstractBackgroundWolff–Parkinson–White (WPW) syndrome is a relatively common arrhythmia affecting ~1–3/1,000 individuals. Mutations in PRKAG2 have been described in rare patients in association with cardiomyopathy. However, the genetic basis of WPW in individuals with a structurally normal heart remains poorly understood. Sudden death due to atrial fibrillation (AF) can also occur in these individuals. Several studies have indicated that despite ablation of an accessory pathway, the risk of AF remains high in patients compared to general population.MethodsWe applied exome sequencing in 305 subjects, including 65 trios, 80 singletons, and 6 multiple affected families. We used de novo analysis, candidate gene approach, and burden testing to explore the genetic contributions to WPW.ResultsA heterozygous deleterious variant in PRKAG2 was identified in one subject, accounting for 0.6% (1/151) of the genetic basis of WPW in this study. Another individual with WPW and left ventricular hypertrophy carried a known pathogenic variant in MYH7. We found rare de novo variants in genes associated with arrhythmia and cardiomyopathy (ANK2, NEBL, PITX2, and PRDM16) in this cohort. There was an increased burden of rare deleterious variants (MAF ≤ 0.005) with CADD score ≥ 25 in genes linked to AF in cases compared to controls (P = .0023).ConclusionsOur findings show an increased burden of rare deleterious variants in genes linked to AF in WPW syndrome, suggesting that genetic factors that determine the development of accessory pathways may be linked to an increased susceptibility of atrial muscle to AF in a subset of patients.